Research graph
References from Cytomegalovirus infection in heart transplant recipients: Epidemiology, risk factors, and long-term outcomes from a major transplant center in the United States. Local targets link to admitted publications; unresolved targets remain external evidence.
Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice
10.1111/ctr.13512 · 2019 · External reference
Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials
10.1093/cid/ciw668 · 2017 · External reference
Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
10.2147/idr.s180908 · 2019 · External reference
Cytomegalovirus infection in heart transplantation: a single center experience
10.1111/tid.12896 · 2018 · External reference
Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy
10.1016/j.transproceed.2012.09.035 · 2012 · External reference
Absolute lymphocyte count as marker of cytomegalovirus and allograft rejection: is there a "Safe Corridor" after kidney transplantation?
10.1111/tid.13489 · 2021 · External reference
Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation
2018 · External reference
Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients
10.1111/j.1600-6143.2005.00797.x · 2005 · External reference
Cytomegalovirus infections in solid organ transplantation: a review
10.3947/ic.2013.45.3.260 · 2013 · External reference
Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation
10.1111/j.1600-6143.2011.03636.x · 2011 · External reference
Resistant cytomegalovirus in intestinal and multivisceral transplant recipients
10.1111/tid.12507 · 2016 · External reference
Infections in intestinal and multivisceral transplant recipients
10.1016/j.idc.2013.02.012 · 2013 · External reference
Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment
10.1007/s11908-012-0292-2 · 2012 · External reference
The REDCap consortium: building an international community of software platform partners
10.1016/j.jbi.2019.103208 · 2019 · External reference
Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support
10.1016/j.jbi.2008.08.010 · 2009 · External reference
Absolute lymphocyte count as a marker for cytomegalovirus infection after heart transplantation
10.1097/tp.0000000000004360 · 2023 · External reference
Cytomegalovirus infection in solid organ transplantation: economic implications
10.2165/00019053-200321070-00002 · 2003 · External reference
Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients
10.1186/s12879-015-1321-1 · 2015 · External reference
Impact of cytomegalovirus serologic status on heart transplantation
10.1111/jocs.14588 · 2020 · External reference
Incidence and severity of cytomegalovirus infection in seropositive heart transplant recipients
10.1111/ctr.14982 · 2023 · External reference
The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients
10.1111/j.1600-6143.2010.03074.x · 2010 · External reference
Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive/recipient seronegative heart transplant recipients
10.1111/tid.13255 · 2020 · External reference
Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
10.2147/dddt.s36578 · 2012 · External reference
Prevention and treatment of cytomegalovirus disease in heart transplant patients
10.1016/s1053-2498(00)00096-6 · 2000 · External reference
Effect of preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial
10.1001/jama.2020.3138 · 2020 · External reference
Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation
10.1016/j.healun.2003.08.034 · 2004 · External reference
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
2013 · External reference
Utility of cytomegalovirus cell-mediated immunity assays in solid organ transplantation
10.1128/jcm.01716-21 · 2022 · External reference
Diagnostic performance of cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in kidney transplantation: a PRISMA-compliant article
10.1097/md.0000000000015228 · 2019 · External reference
Immune monitoring for CMV in transplantation
10.1007/s11908-018-0610-4 · 2018 · External reference
Utility of CMV-specific immune monitoring for the management of CMV in solid organ transplant recipients: a clinical update
2021 · External reference
Twice as nice: cytomegalovirus tele-education
10.1111/tid.13865 · 2022 · External reference
Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients
10.1093/cid/ciy295 · 2018 · External reference
Epidemiology, risk factors, and outcomes associated with cytomegalovirus in adult kidney transplant recipients: A systematic literature review of real-world evidence
10.1111/tid.13483 · 2021 · External reference
Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients
10.1093/ofid/ofz003 · 2019 · External reference
Association between cytomegalovirus infection and allograft rejection in a large contemporary cohort of heart transplant recipients
10.1111/tid.13569 · 2021 · External reference
Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir
10.1086/324516 · 2001 · External reference
Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients
10.1016/j.healun.2009.02.009 · 2009 · External reference
Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study
10.1111/j.1399-3062.2010.00573.x · 2011 · External reference
A multivariate analysis of the risk of cytomegalovirus infection in heart transplant recipients
10.1093/infdis/157.3.515 · 1988 · External reference
Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group
1994 · External reference
Post-transplant absolute lymphocyte count predicts early cytomegalovirus infection after heart transplantation
2021 · External reference
